Halozyme Therapeutics, Inc. (LON: 0J2O)
London
· Delayed Price · Currency is GBP · Price in USD
56.51
-0.10 (-0.18%)
At close: Jan 31, 2025
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $290.08M USD in the quarter ending September 30, 2024, with 34.28% growth. This brings the company's revenue in the last twelve months to $947.36M, up 21.35% year-over-year. In the year 2023, Halozyme Therapeutics had annual revenue of $829.25M with 25.62% growth.
Revenue (ttm)
$947.36M
Revenue Growth
+21.35%
P/S Ratio
n/a
Revenue / Employee
$2.54M
Employees
373
Market Cap
5.80B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Halozyme Therapeutics News
- 25 days ago - Halozyme raises 2025 guidance, announces $250M stock buyback - Seeking Alpha
- 25 days ago - Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PRNewsWire
- 27 days ago - Halozyme Therapeutics Inc (HALO) Announces Investor Conference Call for 2025 Financial Guidance - GuruFocus
- 27 days ago - Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - PRNewsWire
- 4 weeks ago - Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025 - Seeking Alpha
- 4 weeks ago - Halozyme: Recent Approvals Alter My Appetite - Seeking Alpha
- 4 weeks ago - Halozyme Therapeutics Inc (HALO) Announces Regulatory Approval for HYQVIA® in Japan - GuruFocus
- 4 weeks ago - FDA Approves Halozyme's ENHANZE-Enabled Opdivo Qvantig for Subcutaneous Use - GuruFocus